3:17 PM
Sep 07, 2017
 |  BioCentury  |  Emerging Company Profile

Coating calcifications

How Inositec aims to treat vascular calcification in CKD patients

Inositec AG aims to halt vascular calcification in patients with chronic kidney disease by making analogs of the calcium chelator inositol hexaphosphate that are safer and more drug-like than the natural product.

According to co-founder and CEO Mattias Ivarsson, research over the last 10 years has linked poor CV outcomes in the chronic kidney disease (CKD) population to development of vascular calcification, a process that occurs when high concentrations of calcium phosphate in the blood trigger formation of mineral deposits in the vascular wall. Over time, buildup of the deposits causes vascular stiffening and occlusions.

“We believe that the calcification is really a key driver in the cardiovascular disease in these patients,” Ivarsson told BioCentury.

Naturally occurring inositol hexaphosphate (IP6), found in many edible plants, has long been recognized as a strong chelator of calcium ions due to its high charge. Yet Ivarsson said the molecule has limited therapeutic potential because of its poor PK profile, which includes fast...

Read the full 785 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >